title: Reply to: Need for improvements in reported cost-effectiveness of adalimumab in rheumatoid arthritis.
authors.affiliation: Junior Chair of Health Economics, Justus Liebig University Giessen, Licher Str. 62, Giessen, 35394, Germany. cg@phec.de.
authors.forename: C
authors.initials: C
authors.lastname: Gissel
authors.affiliation: Chair for Industrial Organization, Regulation and Antitrust, Justus Liebig University Giessen, Giessen, Germany.
authors.forename: G
authors.initials: G
authors.lastname: Götz
authors.affiliation: Department of Medicine, Justus Liebig University Giessen, Giessen, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Repp
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D001172:Arthritis, Rheumatoid; D003362:Cost-Benefit Analysis; D000068800:Etanercept; D006801:Humans; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab; D000068800:Etanercept